VHH and nanobody design

Camelids make antibodies that have no light chain. The antigen-binding domain of those antibodies, the VHH, is a single folded domain of roughly fifteen kilodaltons that binds on its own. Sharks make something analogous. Because the domain is small, stable and easy to express, VHHs have become a standard format for research reagents, imaging, intracellular binders and an increasing number of therapeutics.

What makes a VHH soluble on its own

A conventional VH is not soluble by itself, because one face of it is built to pack against a light chain. In a VHH, that face carries a small set of hallmark substitutions in framework 2 that replace hydrophobic residues with smaller, more polar ones. The domain also tends to have a longer CDR3, which often folds back over the former light chain interface and, in many families, is pinned by an extra disulfide to framework 2 or to CDR1.

Those two features explain most of the format's behavior. The long, convex CDR3 gives VHHs a paratope shape that reaches into clefts and enzyme active sites, where a flat antibody interface struggles. The framework substitutions keep the domain soluble and reversibly foldable, which is why VHHs tolerate heat and expression in the cytoplasm better than most Fv fragments.

Where the format wins

• Cryptic and concave epitopes, including active sites and receptor pockets.
• Modularity. Tandem fusions, biparatopic pairs and fusions to Fc, albumin binders, enzymes or toxins are straightforward because there is one chain to work with.
• Expression. Many VHHs express well in bacterial and yeast systems as well as mammalian cells, which makes large panels cheap.
• Stability. Small, disulfide-pinned domains that refold are easier to formulate and easier to ship.
• Intracellular use. Some VHHs fold in the reducing environment of the cytoplasm, which is the basis of the intrabody work that conventional fragments cannot do.

What it costs

A single domain has no light chain to help, so paratope surface area is smaller, and picomolar affinity from a naive source is less common than with paired chains.

Half-life is short. A fifteen kilodalton protein clears through the kidney quickly, so therapeutic VHHs are usually fused to an Fc or to an albumin binding module, and that fusion changes the molecule's properties enough to require re-testing.

Immunogenicity needs thought. Camelid frameworks are close to human VH3 but not identical, and humanization is a normal step for clinical work, done carefully because the hallmark residues that keep the domain soluble sit exactly where humanization wants to edit.

Finally, the long CDR3 that gives the format its reach is also the part most likely to carry developability liabilities, and it is the part you least want to change.

Designing them

The practical pipeline is the same as for other binders: generate candidates, filter for developability, predict structure, simulate the shortlist, then build and test. Two format-specific notes matter. First, run the numbering and the liability analysis with a scheme that handles VHH properly, since a VHH is not a VH. Second, decide the final format early. A VHH that behaves well as a monomer can behave differently as a VHH-Fc, because avidity changes both apparent affinity and the assay you use to measure it.